Policy

TrumpRx will include more than 600 generic medications; experts say the platform’s impact on high-cost specialty drug affordability may be limited.

This study evaluated differences in racial and ethnic disparities in surgical outcomes between Medicare Advantage and traditional Medicare beneficiaries, finding consistent but nonuniform smaller disparities within Medicare Advantage.

Women’s Health Month highlights major 2026 shifts in menopause care, brain health, abortion access, doula coverage, and wearable tech.

Health updates cover abortion pill access, lung care research, pregnancy-linked heart risks, US longevity gaps, and flawed drug adherence metrics.

Prior authorization and payer hurdles delay prescription drugs; the Alliance for Patient Access urges health policy shaped by patient experience.

There were about 70,000 Americans who died of drug overdoses in 2025, which continues a decline in drug overdoses that has lasted 3 years.

Preoperative acute care costs significantly predicted postoperative costs in Bundled Payments for Care Improvement model year 3 surgeries, suggesting that accounting for preoperative factors may improve bundled payment outcomes.

From rewriting drug approval standards to embedding AI in review workflows, former FDA commissioner Marty Makary, MD reshaped how evidence, speed, and access are balanced in US drug regulation.

Food insecurity identification modeling for Medicare can establish a reliable method of prioritizing members at risk of food insecurity for identification and program enrollment.

Scott Shannon, MD, discusses psychedelic therapies, federal policy shifts, and the barriers slowing mental health innovation.

Amid disagreements between the FDA and White House on drug approvals, vapes, and mifepristone, the tenure of Marty Makary, MD, as commissioner has come to an end.

Fears that the telemedicine boom would send health care costs soaring haven’t been borne out, a major new study finds, and the timing couldn’t be more critical for federal policy makers.

Private equity’s growing influence on American health care has outpaced regulatory oversight. Stronger policies are necessary to safeguard patients, providers, and care delivery.

From psychedelics to abortion pills, drug pricing, crisis lines, and cancer care, new policies reshape access—and expose gaps patients still face.

Here is a policy briefing for chief medical officers and managed care leaders on key pressure points about the Medicaid funding cuts.

Their study found cost nudges had minimal effect on clinic selection, as 85% already chose lower-cost tiers, suggesting tiered benefit design works.

Chris Johnson, MBA, discusses how Medicaid incentives and higher primary-care pay can boost preventive pediatric care.

White House projects $600B in savings from MFN drug pricing plan, with major implications for GLP-1 access, Medicaid, and biologics.

Muhammad Bilal Abid, MD, discusses COVID prevention gaps, monoclonal antibodies, and infection risk in immunocompromised patients with CLL.

Evidence suggests that adoption of oncology biosimilars in Medicare value-based payment models has produced substantial cost savings and improved provider financial performance.

New executive order fast-tracks psychedelic therapy research for veterans, but VA rollout, DEA rescheduling, and insurance hurdles still loom.

Experts dismantled the assumption that direct-to-patient is a universal affordability solution, offering manufacturers a practical framework for deciding which model is actually right.

Lessons learned from developing an inferential model for predicting food insecurity yield essential insights and actionable steps for policy makers seeking to address health-related social needs.

This week, a Capitol hearing spotlights Medicare fraud gaps, reports warn of equity setbacks, community oncology boosts survival, and Medicaid work rules loom.

A new Commonwealth Fund report finds persistent racial health disparities nationwide despite coverage gains, with major gaps in care, access, and outcomes.